Rigel Pharmaceuticals (RIGL) Capital Leases (2010 - 2016)

Rigel Pharmaceuticals' Capital Leases history runs 4 years deep, the most recent figure standing at $238000.0 for Q4 2016.

• In Q4 2016, Capital Leases fell 93.12% year-over-year to $238000.0; the TTM figure through Dec 2016 stood at $238000.0 (down 93.12% YoY), while the FY2016 annual figure was $238000.0, down 93.12% from the prior year.
• Capital Leases for Q4 2016 stood at $238000.0, down from $1.1 million in the prior quarter.
• The five-year high for Capital Leases was $6.5 million in Q4 2014, with the low at $238000.0 in Q4 2016.
• The 3-year median for Capital Leases is $3.5 million (2015), against an average of $3.4 million.
• The sharpest annual moves came in 2015 and 2016: Capital Leases plunged 46.49% in 2015, then plunged 93.12% in 2016.
• Rigel Pharmaceuticals' Capital Leases stood at $6.5 million in 2014, then slumped by 46.49% to $3.5 million in 2015, then sank by 93.12% to $238000.0 in 2016.
• Business Quant data shows RIGL's Capital Leases at $238000.0 in Q4 2016, $1.1 million in Q3 2016, and $1.9 million in Q2 2016.